Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues	$ 5,866,963	$ 4,488,932	$ 9,039,242	$ 8,544,507
Cost of revenues	5,798,796	3,677,355	9,167,408	7,503,370
Research and development	7,600,744	5,796,022	14,404,376	10,554,535
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	9,400,000	0	9,400,000	0
Selling, general, and administrative	8,736,373	7,446,017	19,824,272	16,416,032
Total operating costs and expenses	31,535,913	16,919,394	52,796,056	34,473,937
Operating loss	(25,668,950)	(12,430,462)	(43,756,814)	(25,929,430)
Other expense:
Other income (expense), net	5,354,845	(185,737)	4,808,818	(375,288)
Interest expense	(547,275)	(105,906)	(1,098,239)	(200,062)
Nonoperating Income (Expense), Total	4,807,570	(291,643)	3,710,579	(575,350)
Loss before (benefit) provision for income taxes and noncontrolling interests	(20,861,380)	(12,722,105)	(40,046,235)	(26,504,780)
(Benefit) provision for income taxes	(3,703,363)	47,387	(3,656,730)	94,796
Net loss	(17,158,017)	(12,769,492)	(36,389,505)	(26,599,576)
Less - loss attributable to noncontrolling interests	(31,757)	(164,474)	(76,349)	(312,502)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (17,126,260)	$ (12,605,018)	$ (36,313,156)	$ (26,287,074)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (0.38)	$ (0.40)	$ (0.88)	$ (0.88)
Weighted average common shares outstanding	44,574,796	31,739,417	41,104,127	29,940,128